LRRC36: A Potential Drug Target and Biomarker for Various Diseases

Target Name: LRRC36

NCBI ID: G55282

LRRC36

LRRC36: A Potential Drug Target and Biomarker for Various Diseases

LRRC36 (Long non-coding RNA-rich complex protein 36) is a protein that is expressed in various tissues of the human body. It is a member of the LRNA-rich complex protein (LRCP) family, which is characterized by the presence of a long non-coding RNA (lnc) in the protein sequence. LRCPs are known for their ability to interact with lncRNAs and are involved in the regulation of gene expression.

The LRCP family has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. LRRC36 is a potential drug target due to its involvement in the regulation of gene expression and its potential role in the development of certain diseases.

LRRC36 has been shown to play a role in the regulation of stem cell proliferation and differentiation. LRRC36 has been shown to interact with the protein Myb, which is involved in the regulation of stem cell proliferation and differentiation. This interaction between LRRC36 and Myb suggests that LRRC36 may be a useful drug target for the treatment of stem cell disorders, such as cancer.

LRRC36 has also been shown to be involved in the regulation of cell adhesion. LRRC36 has been shown to interact with the protein Zeb1, which is involved in the regulation of cell adhesion. This interaction between LRRC36 and Zeb1 suggests that LRRC36 may be a useful drug target for the treatment of diseases characterized by disrupted cell adhesion, such as cancer.

LRRC36 has also been shown to play a role in the regulation of inflammation. LRRC36 has been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation. This interaction between LRRC36 and NF-kappa-B suggests that LRRC36 may be a useful drug target for the treatment of inflammatory diseases.

In addition to its potential role as a drug target, LRRC36 has also been shown to have potential as a biomarker. LRRC36 has been shown to be expressed in various tissues of the human body, including the brain, heart, and pancreas. This suggests that LRRC36 may be a useful biomarker for the diagnosis and monitoring of various diseases.

LRRC36 is also known to have potential as a therapeutic agent. LRRC36 has been shown to be capable of inhibiting the activity of the protein NF-kappa-B, which is involved in the regulation of inflammation. This suggests that LRRC36 may be a useful therapeutic agent for the treatment of inflammatory diseases.

In conclusion, LRRC36 is a protein that has potential as a drug target and biomarker for the treatment of various diseases. Its involvement in the regulation of stem cell proliferation and differentiation, cell adhesion, and inflammation makes it a promising target for therapeutic intervention. Further research is needed to determine the full potential of LRRC36 as a drug and biomarker.

Protein Name: Leucine Rich Repeat Containing 36

The "LRRC36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets